Previous 10 | Next 10 |
Denali Therapeutics press release (NASDAQ:DNLI): Q1 GAAP EPS of -$0.53 misses by $0.03. Revenue of $42.14M (+432.1% Y/Y) beats by $8.82M. For further details see: Denali Therapeutics GAAP EPS of -$0.53 misses by $0.03, revenue of $42.14M beats by $8.82M
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial re...
Denali Therapeutics (NASDAQ:DNLI) said its partner Sanofi (SNY) began dosing in a phase 2 of SAR443820 (DNL788) in individuals with amyotrophic lateral sclerosis (ALS). Under the collaboration agreement, South San Francisco, Calif.-based Denali will receive $40M as milestone payment...
Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with amyotrophic lateral sclerosis (ALS) Denali to receive a milestone payment of $40 million from Sanofi for Phase 2 clinical trial initiation Development of RIPK1 inhibitor ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arcus Biosciences (NYSE: RCUS ): Cancer biotech having multiple big-pharma collaborations that ensure revenue streams Vir Biotechnology (NASDAQ: VIR ): Diversified infectious disease play BioNTech (N...
Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia among the elderly, accounting for between 60% and 80...
The following slide deck was published by Denali Therapeutics Inc. in conjunction with this event. For further details see: Denali Therapeutics (DNLI) Presents At Oppenheimer 32nd Annual Healthcare Virtual Conference - Slideshow
Denali Therapeutics (NASDAQ:DNLI), a clinical-stage biotech focused on neurodegenerative diseases, announced on Tuesday that the company’s Chief Operating Officer Alexander Schuth would add the Chief Financial Officer role to his current responsibilities. A decision by the current CFO,...
SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that Stev...
Denali Therapeutics (NASDAQ:DNLI) said dosing began in a phase 1/2 trial of DNL593 to treat a type of dementia called frontotemporal dementia (FTD) caused by mutations in the granulin gene (GRN). Denali has partnered with Takeda Pharmaceutical (NYSE:TAK) to co-develop and co-commerc...
News, Short Squeeze, Breakout and More Instantly...
Denali Therapeutics Inc. Company Name:
DNLI Stock Symbol:
NASDAQ Market:
Denali Therapeutics Inc. Website:
2024-07-10 22:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological products for rare diseases DNL126 was selected as one of three CDER-regulated products based on eligibility criteria including the potentia...
2024-05-10 10:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...